Michael Gelband’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Michael Gelband’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Sell	33,017 -19,286	-37%	-$1M	0.01%	800
2026 Q1	$2.52M	Buy	52,303 +44,345	+557%	+$1.96M	0.02%	684
2025 Q4	$328K	Sell	7,958 -51,918	-87%	-$2.08M	﹤0.01%	1285
2025 Q3	$2.32M	Sell	59,876 -73,400	-55%	-$2.38M	0.02%	690
2025 Q2	$3.69M	Buy	133,276 +100,894	+312%	+$2.57M	0.03%	510
2025 Q1	$719K	Sell	32,382 -94,779	-75%	-$1.95M	0.01%	1012
2024 Q4	$2.52M	Buy	127,161 +115,223	+965%	+$2.63M	0.02%	643
2024 Q3	$298K	Buy	+11,938	New	+$291K	﹤0.01%	1360
2024 Q1	–	Sell	-83,572	Closed	-$1.47M	–	1737
2023 Q4	$1.47M	Buy	+83,572	New	+$1.37M	0.01%	677
2023 Q2	–	Sell	-16,994	Closed	-$183K	–	2064
2023 Q1	$183K	Buy	+16,994	New	+$224K	﹤0.01%	1583
2022 Q1	–	Sell	-19,157	Closed	-$225K	–	2438
2021 Q4	$225K	Sell	19,157 -20,830	-52%	-$256K	﹤0.01%	1782
2021 Q3	$455K	Buy	+39,987	New	+$521K	0.01%	1450

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Michael Gelband's KNSA Position: Q2 2026 in Review

Michael Gelband reduced its Kiniksa Pharmaceuticals (KNSA) stake by 37% in Q2 2026, selling an estimated $1M and leaving 33,017 shares worth $2.11M. The position accounts for 0.01% of the portfolio, ranked #800.

Michael Gelband first reported a position in KNSA in Q3 2021 and has held it in 12 quarters since. The position peaked at $3.69M in Q2 2025. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Michael Gelband held 33,017 shares of Kiniksa Pharmaceuticals worth $2.11M as of Q2 2026.
Michael Gelband sold 19,286 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1M.
Kiniksa Pharmaceuticals made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #800 holding.
Michael Gelband first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
Michael Gelband's Kiniksa Pharmaceuticals position peaked at $3.69M in Q2 2025.
265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.